The myths that drive therapeutic inertia in multiple sclerosis: a cost-effectiveness analysis of high-efficacy drugs in Brazil by Leonardo Zumerkorn Pipek, João Vitor Mahler, Rafaela Farias Vidigal Nascimento, Jefferson Becker, Samira Luísa Apóstolos-Pereira, Tarso Adoni, Guilherme Diogo Silva, Dagoberto Callegaro, on behalf of BCTRIMS (Comitê Brasileiro de Pesquisa e Tratamento em Esclerose Múltipla)

Get full text